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Abstract
Background: To investigate indocyanine green angiography (ICGA) findings in patients with long-standing
Vogt-Koyanagi-Harada (VKH) disease and their correlation with disease activity on clinical examination as well as
with systemic corticosteroid therapy.
Methods: Twenty-eight patients (51 eyes) with long-standing (≥6 months from disease onset) VKH disease whose
treatment was tapered based only in clinical features were prospectively included at a single center in Brazil. All
patients underwent standardized clinical evaluation, which included fundus photography, fluorescein angiography
and ICGA. Clinical disease activity was determined based in the Standardization in Uveitis Nomenclature Working
Group. Fisher exact test and logistic regression models were used for statistical analysis.
Results: Disease-related choroidal inflammation on ICGA was observed in 72.5% (31 of 51 eyes). Angiographic
findings suggestive of (choroidal and/or retinal) disease activity were not observed on FA. Clinically active disease
based on clinical evaluation was observed in 41.2% (21 of 51 eyes). In these 21 eyes, disease-related choroidal
inflammation on ICGA was observed in 76.2% (16 of 21 eyes); in the remaining eyes (without clinical active disease)
disease-related choroidal inflammation on ICGA was observed in 70.0% (21 of 30 eyes). In respect to systemic
corticosteroid therapy, 10 patients (18 of 51 eyes) were under treatment with prednisone. In these 10 (18 of 51
eyes) patients, disease-related choroidal inflammation on ICGA was observed in 83.3% (15 of 18 eyes); in the
remaining patients (33 of 51 eyes) disease-related choroidal inflammation on ICGA was observed in 66.7%
(22 of 33 eyes).
Conclusion: ICGA findings suggestive of disease-related choroidal inflammation were observed in a considerable
proportion of patients with long-standing VKH disease, independent of the inflammatory status of the disease on
clinical examination or current use of systemic corticosteroid. Therefore, the current study reinforces the crucial role
of ICGA to assist the management and treatment of patients with long-standing VKH disease.
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Background
Vogt-Koyanagi-Harada (VKH) disease is a T-cell altered
immune process that is directed at the melanocytes [1].
The diagnosis is essentially based on the observation of
bilateral diffuse choroiditis of acute onset following flu-
like prodromic symptoms, and prompt treatment with
systemic corticosteroid and/or immunosuppressant has
been recommended. In spite of aggressive treatment
during the acute phase of the disease, slowly progressive
fundus depigmentation has been observed over time [2],
even in the absence of detectable clinical signs of disease
activity. There is increasing evidence that this slowly
progressive fundus depigmentation is related to some
disease activity undetected on regular clinical examin-
ation and is due to insufficient therapy; it does most
probably not occur as part of the natural history of VKH
disease [3].
In this sense, indocyanine green angiography (ICGA)
may be an interesting ancillary tool. As the dye fluor-
esces in the near infrared wavelength, indocyanine green
is particularly useful for imaging of the choroidal vascu-
lar compartment. In fact, the role of ICGA in detecting
choroidal inflammation in patients with VKH disease
has been investigated [4-7], mainly in European and
Asian countries. Its relevance has been pointed out to
either confirm elements already revealed by clinical
examination or to determine the inflammatory status
of the fundus and monitor VKH disease activity during
follow-up, thus assisting the treatment process [4-7].
The use of ICGA for monitoring VKH disease activity,
however, is not universally accepted [8,9]. Moreover,
some of the ICGA findings suggestive of choroidal in-
flammation related to the disease may share angio-
graphic features with those findings observed in patients
under systemic corticosteroid treatment [10-13]. In the
current report, we studied the ICGA findings in patients
with long-standing VKH disease (i.e., patients who had
more than 6 months from disease onset, regardless of
the disease activity status determined on clinical examin-
ation). The possible correlation between ICGA findings
and clinical disease activity as well as systemic cortico-
steroid therapy was investigated.
Methods
Subjects
Patients with long-standing VKH disease were prospect-
ively enrolled in the study from March 2007 through
October 2008 at a single center in Brazil (Uveitis Service,
Hospital das Clínicas, Universidade de São Paulo, São
Paulo, SP, Brazil) after written informed consent was
obtained.
The diagnosis of VKH disease was based on the
Revised Diagnostic Criteria proposed by the Inter-
national Committee on Nomenclature [14]. Patients who
were eligible for inclusion in the study had been treated
during the acute phase with oral prednisone adminis-
tered at 1.0-1.5 mg/kg daily, which was tapered accord-
ing to disease activity over a period of time of at least
6 months. During this period disease activity was deter-
mined based on clinical examination and on fluorescein
angiography (FA) findings.
The characterization of long-standing disease was
based in the presence of a minimum time interval of
6 months from the onset of VKH disease, independently
of the current clinical [phase] status of the disease.
Patients with known allergy to fluorescein and/or indo-
cyanine green dyes and media opacities that could pre-
vent adequate fundus imaging were not eligible for study
participation.
During the study period, disease activity was deter-
mined based on clinical evaluation, in accordance to the
Standardization of Uveitis Nomenclature (SUN) Work-
ing Group [15]. Those eyes presenting cells in the anter-
ior or posterior chamber or disc hyperemia, as well as
any sign suggestive of posterior inflammation (for ex-
ample, optic disc hyperfluorescence) on FA, were con-
sidered to have clinically active disease. Patients with
clinically active disease by the time of initial study evalu-
ation were treated with topical corticosteroid, associated
or not with oral prednisone and/or immunosuppressant.
Fundus photography and angiographic studies
Eligible patients underwent fundus photography (color
and red-free) as well as angiographic studies (fluorescein
and indocyanine green) using a conventional fundus
camera system (TRC-50IX/IMAGEnet; Topcon Inc.,
Tokyo, Japan). Angiographic studies followed a standar-
dized protocol previously described for the investigation
of inflammatory eye diseases [16], and the eye with more
pronounced fundus changes on clinical examination was
selected for documentation of the initial transit phase of
the dyes.
The ICGA data were evaluated by a retina specialist in
a masked fashion. The following ICGA findings were
categorically analyzed: 1) diffusely leaking choroidal ves-
sels in the intermediate phase (“fuzzy vessels”), 2) diffuse
choroidal hyperfluorescence in the late phase, and 3)
hypofluorescent dark dots in the intermediate phase
with later isofluorescence [6,7,16]. Those eyes presenting
at least 2 of these findings were considered to have
disease-related choroidal inflammation on ICGA.
Ethics
This study protocol followed the statements of the Dec-
laration of Helsinki and was approved by the Ethics in
Research Committee analyzing research projects-
CAPPesq from the Clinical Board of the Medical School
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of the University of São Paulo, under protocol #10121/
2008.
Statistical analysis
The correlation between the ICGA findings (i.e., disease-
related choroidal inflammation) and disease activity on
clinical examination (i.e., clinical activity) at the time of
the angiographic study was evaluated using Fisher exact
test. Logistic regression models were used to analyze the
relationship between disease-related choroidal inflamma-
tion on ICGA and clinical activity as well as the use of
systemic corticosteroid therapy. Data analysis and statis-
tical tests were done using SPSS 15.0 (SPSS Science,
Chicago, Illinois, USA) statistical software. The signifi-
cance level was set at 0.05 for all tests.
Results
Twenty-eight patients with long-standing VKH disease
(51 eyes) were included in the study (in 5 patients, one
eye was excluded due to media opacities). The ICGA
findings were correlated with clinical activity and sys-
temic corticosteroid therapy. The baseline characteristics
are presented in Table 1.
At least one individual ICGA feature was observed in
patients with long-standing VKH disease. The fuzzy ves-
sels were observed in 80.4% (41 of 51 eyes), late diffuse
hyperfluorescence in 78.4% (40 of 51 eyes), and dark
dots in the intermediate phase with later isofluorescence
in 19.6% (10 of 51 eyes). The presence of at least 2 of
these ICGA features, thus characterizing disease-related
choroidal inflammation on ICGA, was observed in
72.5% (37 of 51 eyes) (Figure 1). On FA, all eyes exhib-
ited areas of hypofluorescence due to blockage inter-
spersed with areas of hyperfluorescence due to window
defects. Late hyperfluorescence due to staining of sub-
retinal fibrovascular tissue was also observed in 37.3%
(19 of 51 eyes). FA findings suggestive of (choroidal and/
or retinal) disease activity were not observed.
In respect to clinical activity, 41.2% (21 of 51 eyes)
were considered to have clinically active disease based
on clinical evaluation. In all 21 eyes clinical signs indica-
tive of some degree of anterior chamber inflammation
(cells + to +++) were observed on clinical examination.
Clinical signs suggestive of inflammation of the posterior
segment were not observed on clinical examination.
In respect to systemic corticosteroid therapy, 10
patients (18 of 51 eyes) were under treatment with pred-
nisone (with or without immunosuppressant agents).
Three patients (5 of 51 eyes) were under treatment with
immunosuppressant agents, and 15 patients (28 of 51
eyes) were using only topical treatment (Table 2).
The possible correlation of disease-related choroidal
inflammation on ICGA with clinical activity and with
systemic corticosteroid therapy was evaluated. In the 21
eyes with clinically active disease based on clinical evalu-
ation disease-related choroidal inflammation on ICGA
was observed in 76.2% (16 of 21 eyes). In the remaining
30 eyes (without clinical active disease) disease-related
choroidal inflammation on ICGA was observed in 70.0%
(21 of 30 eyes). In the patients (18 of 51 eyes) under sys-
temic corticosteroid therapy, disease-related choroidal
inflammation on ICGA was observed in 83.3% (15 of 18
eyes); in the remaining patients (33 of 51 eyes) disease-
related choroidal inflammation on ICGA was observed
in 66.7% (22 of 33 eyes).
Discussion
The current study demonstrated that ICGA findings
suggestive of disease-related choroidal inflammation was
observed in a considerable proportion of patients with
long-standing VKH disease whose treatment was tapered
according to clinical and FA evaluation. Disease-related
choroidal inflammation on ICGA was highly prevalent
even among patients under systemic treatment as well
as among those with no clinically detectable disease
Table 1 Demographics and clinical characteristics of the
patients with Vogt-Koyanagi-Harada and long-standing
disease
Description
Number of patients (eyes) 28 (51)
Age (years), mean (± 1SD) 39.9 ±13.0
Gender, male (%) 4 (14.3)
Race, n (%)
White 12 (42.8)
Mestizo 10 (35.7)
Black 4 (14.3)
Asian/Oriental 2 (7.1)
Revised Diagnostic Criteria category [14], n (%)
Complete 7 (25.0)
Incomplete 14 (50.0)
Probable 7 (25.0)
Clinical activity (SUN) [15], n (%)
Remission} 11 (39.3)
Inactive} 5 (17.8)
Active 12 (42.8)
Use of systemic medication, n (%)
Prednisone only 5 (17.8)
Prednisone and immunosuppressant 5 (17.8)
Immunosuppressants only 3 (10.7)
None 15 (53.6)
Disease duration (in months), median (range) 91.5 (9–348)
}Inactive disease for ≥3 months after discontinuing all treatments for eye
disease.
} Grade 0 cells.
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activity, thus confirming previous studies in European
and Asian population and reinforcing the usefulness of
ICGA to assist monitoring disease activity to better
tailor treatment strategies.
Bouchenaki and Herbort described ICGA findings sug-
gestive of choroidal involvement in acute VKH disease,
which were less evident in the chronically evolving dis-
ease, and proposed ICGA as a useful tool to monitor the
effect of steroid therapy [7]. Subtle ICGA findings in
patients with VKH disease were subsequently shown to
represent otherwise unnoticeable posterior segment
disease-related activity [4-6]. These findings were
described in the context of VKH disease during anterior
segment relapses in the chronic phase and in patients
tapering treatment in the convalescent phase of the dis-
ease. In both scenarios, intensification of immunosup-
pressive treatment resolved both, clinically apparent as
well as the underlying disease process. Kawaguchi et al.
coined the term partially treated VKH disease to de-
scribe patients in the convalescent phase whose treat-
ment was intense enough to abolish anterior segment
activity while leaving signs of choroidal involvement on
ICGA, and who experienced progressive fundus depig-
mentation (sunset-glow fundus) [4]. In the current study,
roughly three quarters of the eyes with long-standing
VKH disease presented ICGA findings suggestive of
disease-related choroidal inflammation regardless of the
presence of activity on clinical examination. In fact, 70.0%
of eyes demonstrated disease-related choroidal inflamma-
tion on ICGA without clinical evidence of disease activity,
thus suggesting the presence of subclinical choroidal in-
flammation. Considering treatment regimen by the time
of disease diagnosis, the majority of the patients included
in this study had received early high-dose treatment.
However, they were not systematically monitored with
ICGA during the systemic treatment course, and clinical
appraisal and fluorescein angiography were the only para-
meters used to taper treatment. Coupled with previous
reports of better outcomes in more intensely treated
patients, these observations provide additional evidence
to support the possible role of ICGA in the adjustment
of therapy at this stage of VKH disease [4,5,14-17]. The
Figure 1 Color fundus photography (A) as well as early, mid and late phase indocyanine green angiography (B,C,D, respectively) from
a representative patient with Vogt-Koyanagi-Harada and long-standing disease. Note “fuzzy vessels” (arrows) on early and mid phases
ICGA, and “late diffuse hyperfluorescence” (curved arrows) on late phase of the exam.
Table 2 Correlation between disease-related choroidal
inflammation on indocyanine green angiography, clinical
disease activity and systemic corticosteroid therapy in 28
patients (51 eyes) with Vogt-Koyanagi-Harada and long-
standing disease
N (eyes) Disease-related choroidal
inflammation on ICGA, n (%)
p
Total number of eyes 51 37 (72.5)
Anterior chamber inflammation (cells)
Yes 21 16 (76.2) 0.626†
No 30 21 (70.0)
Systemic treatment at the time of ICGA
Prednisone 18 15 (83.3) 0.326†
Immunosuppressant 5 3 (60.0)
No 28 19 (67.8)
†Results of Fisher’s exact test.
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importance of ICGA guided management of VKH disease
to meaningfully assess choroidal inflammation has been
recently reinforced by Bouchenaki and Herbort [3]. These
authors proposed that zero tolerance to subclinical chor-
oidal inflammation could avoid irremediable evolution to-
wards sunset glow fundus [3].
In the current study, fuzzy vessels and late diffuse
hyperfluorescence were the most frequently findings
observed on ICGA, thus suggesting some alteration in
choroidal vessels’ permeability and choriocapillaris in-
volvement [6]. Dark dots were considered only if they
became isofluorescent (or mildly hyperfluorescent) in
late-phase frames [6], and were the least observed ICGA
finding in the current study. These observations are in
line with previous histopathologic studies in patients
with VKH and chronic disease in which a diffuse, non-
granulomatous choroiditis accompanied by choriocapil-
laris involvement was described [1]. Additional findings
identifiable on angiographic studies that have been cor-
related to serious ocular manifestations and/or severe
choroidal inflammation at the acute uveitic stage of
VKH disease [18-21], such as the presence of choroidal
folds as reported by Wu et al.. [18], were not identified
in the current study.
Disease-related choroidal inflammation on ICGA was
apparently more easily observed among those patients
with milder fundus changes than in those with more se-
vere fundus changes in the current study (Figure 2;
Additional file 1: Table S3) [22,23]. It is possible that
some eyes with fundus-based severe disease could also
present subclinical choroidal inflammation that remains
undetected on ICGA due to a combination of factors,
such as the limited ability to identify ICGA signs of
choroidal inflammation in a severely altered fundus with
destruction and scarring of a considerable proportion of
the choroidal stroma [6]. Naturally, the identification of
the ICGA findings indicative of choroidal inflammation
in patients with mild fundus changes seems an easier
task. It should be noted that this study has limitations
due to the relatively small number of patients and its cross-
sectional design. In addition, the misinterpretation of the
ICGA findings should always be considered in studies of
this nature. Future studies, combining ICGA with other
fundus imaging modalities such as fundus autofluorescence
and enhanced depth imaging optical coherence tomo-
graphy may facilitate our understanding of the choroidal in-
volvement in patients with VKH disease [24,25],
independent of the severity of disease associated fundus
alterations.
Conclusions
In the current study a considerable proportion of
patients with long-standing VKH disease whose treat-
ment was tapered based only on clinical and FA findings
demonstrated ICGA findings suggestive of disease-
related choroidal inflammation. Importantly, we have
also demonstrated that these ICGA findings, which
share some angiographic features with those associated
with corticosteroid treatment, were observed independ-
ent of the use of systemic corticosteroid. Therefore, we
herein provide additional evidence to support the use of
ICGA for the detection of subclinical inflammation in
patients with long-standing VKH disease, which may as-
sist the management and treatment process of this en-
tity, particularly in eyes with milder disease-related
fundus changes.
Additional file
Additional file 1: Table S3. Correlation between indocyanine green
angiography findings and fundus-based disease severity (as per
standardized analytic framework for ocular fundus alterations [22,23]) in
28 patients (51 eyes) with Vogt-Koyanagi-Harada and long-standing
disease.
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